ClearPoint Neuro, Inc. (CLPT)
NASDAQ: CLPT · Real-Time Price · USD
16.47
-0.07 (-0.39%)
Nov 11, 2025, 9:50 AM EST - Market open
ClearPoint Neuro Revenue
ClearPoint Neuro had revenue of $8.86M in the quarter ending September 30, 2025, with 9.10% growth. This brings the company's revenue in the last twelve months to $34.33M, up 12.83% year-over-year. In the year 2024, ClearPoint Neuro had annual revenue of $31.39M with 31.04% growth.
Revenue (ttm)
$34.33M
Revenue Growth
+12.83%
P/S Ratio
13.48
Revenue / Employee
$298,539
Employees
115
Market Cap
467.99M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 31.39M | 7.44M | 31.04% |
| Dec 31, 2023 | 23.96M | 3.40M | 16.56% |
| Dec 31, 2022 | 20.55M | 4.25M | 26.09% |
| Dec 31, 2021 | 16.30M | 3.47M | 27.05% |
| Dec 31, 2020 | 12.83M | 1.61M | 14.37% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
CLPT News
- 4 days ago - ClearPoint Neuro Reports Third Quarter 2025 Results - Accesswire
- 4 days ago - ClearPoint Neuro Announces Agreement to Acquire IRRAS - Accesswire
- 5 days ago - ClearPoint Neuro to Participate in Multiple Global Healthcare Conferences in the Fourth Quarter of 2025 - Accesswire
- 4 weeks ago - ClearPoint Neuro Announces Promising Results from Brain Tumor Laser Therapy Study to be Presented at the CNS Annual Meeting in Los Angeles - Accesswire
- 5 weeks ago - ClearPoint Neuro Announces Expanded International Clearances for Key Therapy Delivery Product; Now Totaling 34 Countries Worldwide - Accesswire
- 5 weeks ago - ClearPoint Neuro: AMT-130 Highlights A Bright Future - Seeking Alpha
- 5 weeks ago - ClearPoint Neuro Announces Development and Demonstration of the Company's Proprietary Robotic Neuro-Navigation System - Accesswire
- 6 weeks ago - ClearPoint Neuro: Selling The Tools For Brain Therapies - Seeking Alpha